1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Insomnia - Drugs In Development, 2022, provides an overview of the Insomnia (Central Nervous System) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Insomnia is a sleep disorder that is characterized by difficulty falling and/or staying asleep. Symptoms include difficulty falling asleep at night, irritability, depression or anxiety, tension headaches and distress in the stomach and intestines. Risk factors include age, mental health disorder, stress and shift working.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Insomnia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Insomnia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Insomnia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Insomnia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 7, 7, 5, 7 and 6 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.
Insomnia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Insomnia (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Insomnia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Insomnia (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Insomnia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Insomnia (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Insomnia (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Insomnia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Insomnia - Overview
- Insomnia - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Insomnia - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Insomnia - Companies Involved in Therapeutics Development
- Insomnia - Drug Profiles
- Insomnia - Dormant Projects
- Insomnia - Discontinued Products
- Insomnia - Product Development Milestones
- Featured News & Press Releases
- Jul 21, 2022: Zelira's Zenivol, the World's first clinically validated cannabinoid medication for insomnia, achieves regulatory approval in Germany
- Jul 19, 2022: Idorsia announces World Champion Skier, Philanthropist and Entrepreneur Lindsey Vonn as patient ambassador for QUVIVIQ (daridorexant), a Once Nightly Treatment for Insomnia
- Jul 13, 2022: Zenivol reaches significant milestone by receiving formal federal regulatory authority (BFARM) approval in Germany
- Jun 08, 2022: Eisai to present latest data on lemborexant at the 36th Annual SLEEP 2022 Meeting
- May 13, 2022: Idorsia U.S. announces first wave of patients prescribed QUVIVIQ (daridorexant) through partnership with pharmacy services provider
- May 10, 2022: First patients enrolled for Schedule 3 CBD clinical trial for Australian Pharmacy Market
- May 03, 2022: Europe’s first dual orexin receptor antagonist - QUVIVIQ (daridorexant) - granted approval to improve both nighttime symptoms and daytime functioning in adults with chronic insomnia disorder
- May 02, 2022: Idorsia’s new treatment QUVIVIQ (daridorexant) is now available in the US for adults living with insomnia
- Mar 10, 2022: New data for daridorexant in patients with insomnia disorder - including long-term safety and efficacy - to be presented at World Sleep 2022
- Feb 25, 2022: QUVIVIQ (daridorexant) recommended for approval in Europe as a new treatment for adults with insomnia disorder
- Jan 20, 2022: The Lancet Neurology reports impact of daridorexant on both nighttime symptoms and daytime functioning in adults with insomnia
- Jan 10, 2022: Idorsia receives US FDA approval of QUVIVIQ (daridorexant) 25 and 50 mg for the treatment of adults with insomnia
- Jan 10, 2022: Idorsia presents at the 40th J.P. Morgan Healthcare Conference - Ready for first product launches - QUVIVIQ (daridorexant) approved by the US FDA
- Dec 08, 2021: Results for phase I human clinical trial characterising CBD absorption from Avecho’s soft-gel capsule
- Oct 04, 2021: Dosing commences for phase I human clinical trial measuring CBD absorption in healthy volunteers
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Insomnia, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Insomnia - Dormant Projects, 2022
- Insomnia - Discontinued Products, 2022
- Number of Products under Development for Insomnia, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Avecho Biotechnology Ltd
- Bod Australia Ltd
- Cannabis Science Inc
- Cennerv Pharma (S) Pte Ltd
- Closed Loop Medicine Ltd
- Eisai Co Ltd
- EUSOL Biotech Co Ltd
- Evotec SE
- Idorsia Pharmaceutical Ltd
- Imbrium Therapeutics LP
- Intra-Cellular Therapies Inc
- Johnson & Johnson
- LP Pharmaceutical (Xiamen) Co Ltd
- M et P Pharma AG
- NB Health Laboratory Co Ltd
- Neurim Pharmaceuticals Ltd
- Neurofix Pharma SA
- NovaMedica
- Servatus Ltd
- Shackelford Pharma Inc
- Sinsin Pharmaceutical Co Ltd
- Taisho Pharmaceutical Holdings Co Ltd
- Yangtze River Pharmaceutical Group
- Zelira Therapeutics Ltd
